ELDN
Eledon Pharmaceuticals, Inc. NASDAQ$3.78
Mkt Cap $226.6M
52w Low $1.35
74.8% of range
52w High $4.60
50d MA $3.07
200d MA $2.61
P/E (TTM)
-6.6x
EV/EBITDA
-1.2x
P/B
2.2x
Debt/Equity
0.0x
ROE
-56.3%
P/FCF
-2.0x
RSI (14)
—
ATR (14)
—
Beta
0.84
50d MA
$3.07
200d MA
$2.61
Avg Volume
1.3M
About
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.20 | -0.10 | +50.0% | 2.85 | +0.7% | +1.1% | +8.8% | +1.4% | +2.5% | +3.9% | — |
| Nov 14, 2025 | AMC | -0.22 | -0.21 | +4.5% | 1.76 | +2.3% | -8.0% | -12.5% | -11.9% | -21.0% | -18.2% | — |
| Aug 14, 2025 | AMC | -0.23 | -0.13 | +43.5% | 2.60 | +1.2% | +1.2% | +0.0% | +0.8% | -0.8% | -1.5% | — |
| May 14, 2025 | AMC | -0.28 | -0.08 | +71.4% | 2.83 | +0.4% | +2.1% | +1.4% | +7.4% | +8.1% | +11.3% | — |
| Mar 20, 2025 | AMC | -0.32 | -0.64 | -100.0% | 3.44 | -2.0% | +2.0% | +4.9% | +0.9% | -2.0% | -0.9% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.32 | -6.7% | 4.82 | -2.3% | -11.4% | -14.3% | -17.0% | -19.1% | -19.5% | — |
| Aug 19, 2024 | AMC | -0.31 | -0.32 | -3.2% | 2.76 | +2.2% | +3.3% | +4.0% | +6.9% | +5.1% | +5.1% | — |
| May 9, 2024 | AMC | -0.37 | -0.34 | +8.1% | 2.40 | +1.2% | -3.8% | -8.8% | -2.5% | +4.6% | +16.7% | — |
| Mar 28, 2024 | AMC | -0.38 | -0.29 | +23.7% | 2.06 | +1.9% | -3.4% | -6.3% | -18.0% | -14.6% | -16.5% | — |
| Nov 9, 2023 | AMC | -0.41 | -0.35 | +14.6% | 1.15 | +1.7% | +0.9% | +4.3% | +8.7% | +8.7% | +8.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $1.62 | $1.61 | -0.6% | -4.9% | -4.3% | -14.2% | -11.1% | -0.6% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.59 | $2.59 | +0.0% | -1.5% | +0.0% | +0.8% | +4.6% | -0.4% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.88 | $3.90 | +0.5% | -0.8% | +4.9% | +3.4% | +3.4% | +9.5% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.81 | +0.4% | +2.5% | +1.4% | -2.9% | -0.7% | +2.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $2.43 | +1.2% | -3.8% | -8.8% | -2.5% | +4.6% | +16.7% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.15 | -11.9% | -7.4% | +0.0% | -1.6% | -5.3% | -10.2% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.88 | $2.07 | +10.1% | +6.9% | +10.1% | +12.8% | +13.3% | +9.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.16 | $1.16 | +0.0% | +3.4% | +7.8% | +7.8% | +7.8% | +9.5% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.42 | +6.8% | +0.8% | +7.5% | +12.0% | +19.9% | +18.8% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.32 | $1.39 | +5.3% | +11.4% | +10.6% | +25.8% | +22.0% | +17.4% |
Recent Filings
Data updated apr 25, 2026 6:50am
· Source: massive.com